Clinical Value of Interim 18 F-FDG PET/CT in Metastatic Non-Small Cell Lung Cancer Treated With First-Line Chemoimmunotherapy: A Prospective Observational Study
Authors:
- Dong Young JeongDJDong Young Jeong
- Wonseok WhiWWWonseok Whi
- Sehhoon ParkSehhoon Park
- You Jin OhYOYou Jin Oh
- Jonghoon KimJKJonghoon Kim
- Jinyong KimJKJinyong Kim
- Jong-Mu SunJong-Mu Sun
- Jin Seok AhnJin Seok Ahn
- Hyun-Ae JungHyun-Ae Jung
- Se-Hoon LeeSe-Hoon Lee
- Joon Young ChoiJoon Young Choi
- Seung Hwan MoonSeung Hwan Moon
Open Access
- 1 January 2027
- journal article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Abstract
Jeong DY, et al. J Korean Med Sci. 2027 Mar;42:e63. https://doi.org/10.3346/jkms.2027.42.e63Keywords
Funding Information
- National Research Foundation of Korea (RS-2024-00334782)
- National Research Foundation of Korea (NRF-2022R1A2C1003999)
- Samsung Medical Center, Sungkyunkwan University (SMO1250061)
- Institute of Information & Communications Technology Planning & Evaluation (RS-2021-II212068)
This publication has 21 references indexed in Scilit:
- 18F-FDG PET/CT for Oncological Patients: Procedural Guideline by the Korean Society of Nuclear Medicine Version 2.0Nuclear Medicine and Molecular Imaging, 2025
- Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living GuidelineAnnals of Oncology, 2025
- [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposalEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- The South Korean health-care system in crisisThe Lancet, 2024
- Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancerScientific Reports, 2022
- Deciphering radiological stable disease to immune checkpoint inhibitorsAnnals of Oncology, 2022
- Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?Journal of Thoracic Oncology, 2019
- Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009